Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is a promising company in the biotechnology sector, with a strong pipeline targeting key factors driving chronic inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Their novel mechanism of action, targeting MRGPRX2 and potentially PACAP signaling, provides potential differentiation in high-value indications like AD and migraine. While facing industry standard issues, their potential for success in additional indications could lead to further upside for investors.

Bears say

Evommune is a clinical-stage biotechnology company with a narrow focus on three key inflammatory diseases. However, the company is facing significant financial challenges, including higher R&D and SG&A costs than estimated and a limited cash flow supporting operations only through 2028. Additionally, competing in crowded markets with established players, such as in the atopic dermatitis market, poses risks to the company's success. Finally, the potential risks of safety and efficacy in the company's pipeline products and the potential for equity dilution also contribute to a negative outlook.

Evommune Inc (EVMN) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 9 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.